Strs Ohio Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Strs Ohio has made a significant investment in Alnylam Pharmaceuticals, acquiring 28,817 shares valued at approximately $7.78 million in the first quarter of the year.
• Alnylam's stock has exhibited strong performance, with a **12-month high of $484.21** and a recent quarterly EPS that exceeded analysts' expectations, reporting $0.32 against a consensus estimate of -$0.54.
• Analysts remain optimistic about Alnylam, with **23 research analysts rating the stock as a Buy** and a consensus target price of $421.28, indicating strong investor confidence.

Strs Ohio purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the first quarter, according to its most recent filing with the SEC. The firm purchased 28,817 shares of the biopharmaceutical company's stock, valued at approximately $7,781,000.

A number of other large investors have also recently bought and sold shares of the business. SVB Wealth LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter valued at about $27,000. Park Square Financial Group LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $28,000. Whipplewood Advisors LLC grew its stake in shares of Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 71 shares during the period. Bessemer Group Inc. grew its stake in shares of Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 69 shares during the period. Finally, Washington Trust Advisors Inc. grew its stake in shares of Alnylam Pharmaceuticals by 53.5% in the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock valued at $47,000 after buying an additional 61 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $465.89 on Monday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $484.21. The stock's 50 day moving average price is $401.46 and its 200-day moving average price is $317.91. The company has a market capitalization of $61.07 billion, a PE ratio of -188.62 and a beta of 0.32. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. The company had revenue of $773.69 million for the quarter, compared to analysts' expectations of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. Alnylam Pharmaceuticals's revenue was up 17.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 6,979 shares of the company's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $453.27, for a total value of $3,163,371.33. Following the completion of the transaction, the chief executive officer directly owned 56,221 shares in the company, valued at approximately $25,483,292.67. The trade was a 11.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jeffrey V. Poulton sold 2,274 shares of the company's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $453.27, for a total transaction of $1,030,735.98. Following the completion of the transaction, the executive vice president owned 50,121 shares of the company's stock, valued at $22,718,345.67. This trade represents a 4.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 75,594 shares of company stock worth $33,968,256. Company insiders own 1.20% of the company's stock.

Analyst Upgrades and Downgrades

ALNY has been the subject of several research reports. Morgan Stanley raised their target price on Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the company an "equal weight" rating in a research note on Friday, August 1st. Evercore ISI raised their target price on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the company an "outperform" rating in a research note on Thursday. HC Wainwright restated a "buy" rating and issued a $570.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, September 2nd. Wolfe Research upgraded Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a research note on Monday, August 4th. Finally, Piper Sandler raised their price target on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the company an "overweight" rating in a research report on Friday, August 1st. Twenty-three research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $421.28.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.